SBUX stock is edging lower despite bullish analyst attention
Analysts are weighing in on biotech stocks ImmunoGen, Inc. (NASDAQ:IMGN) and BeiGene Ltd (ADR) (NASDAQ:BGNE), as well as coffee giant Starbucks Corporation (NASDAQ:SBUX). Here's a quick roundup of today's bullish brokerage notes on shares of IMGN, BGNE, and SBUX.
RBC Sets Major Price Target for IMGN Stock
ImmunoGen stock is up 8% at $7.88 today, and earlier touched an annual high of $8.04, after RBC raised its rating to "outperform" from "sector perform," while also boosting its price target to $12 from $5. This represents territory not seen for IMGN since January 2016, though the shares are up 281% year-to-date. Short sellers have been piling on amid this surge. Specifically, short interest jumped 18% over the past two reporting periods, and now represents 16% of Immunogen's float.
BeiGene Stock Hits Record High on Celgene News
BeiGene stock has rallied 15.8% to trade at $60.55, and earlier hit a record high of $68.67, thanks to news Celgene will buy a stake in the company and help it develop its cancer treatment. BGNE stock has had a great year on the charts, more than doubling in value. Most analysts are already bullish, with all four in coverage rating the stock a "buy" or "strong buy." Just this morning, in fact, Maxim raised its price target to $57 from $52.
SBUX Stock Dips Despite Bull Note
Starbucks stock is down 0.6% at $57.61, despite a Mizuho Securities analyst reiterating a "buy" recommendation amid signs of "substantial growth in mobile order adoption." However, Muslim groups in Malaysia have aligned with protesters in Indonesia, calling for a boycott of the coffee chain over its support of LGBT rights. SBUX stock touched a record high of $64.87 about a month ago, but has since pulled back to float just above its 200-day moving average. The equity's 14-day Relative Strength Index (RSI) is now at 30 -- on the cusp of oversold territory.
Starbucks sports a Schaeffer's put/call open interest ratio (SOIR) of 1.19, in the 87th percentile of its annual range. This means near-term options traders have rarely been more put-heavy on SBUX stock.